Long-term Effectiveness of Varicella Vaccine: A 14-Year, Prospective Cohort Study

@article{Baxter2013LongtermEO,
  title={Long-term Effectiveness of Varicella Vaccine: A 14-Year, Prospective Cohort Study},
  author={Roger Baxter and Paula Ray and Trung Nam Tran and Steven B. Black and Henry R. Shinefield and Paul M Coplan and Edwin M. Lewis and Bruce H. Fireman and Patricia Saddier},
  journal={Pediatrics},
  year={2013},
  volume={131},
  pages={e1389 - e1396}
}
BACKGROUND: Varicella vaccine was licensed in the United States in 1995 for individuals ≥12 months of age. A second dose was recommended in the United States in June 2006. Varicella incidence and vaccine effectiveness were assessed in a 14-year prospective study conducted at Kaiser Permanente Northern California. METHODS: A total of 7585 children vaccinated with varicella vaccine in their second year of life in 1995 were followed up prospectively for breakthrough varicella and herpes zoster (HZ… 

Figures and Tables from this paper

Impact of Vaccination on the Epidemiology of Varicella: 1995–2009

In the 15 years after the introduction of varicella vaccine, a major reduction invaricella incidence and hospitalization was observed with no evidence of a shift in the burden of varICElla to older age groups.

Varicella Vaccine Effectiveness in Preventing Community Transmission in the 2-Dose Era

Two-dose varicella vaccination offered better protection againstvaricella from community transmission among school-aged children compared with 1-dose vaccination.

Impact of a Routine Two-Dose Varicella Vaccination Program on Varicella Epidemiology

Declines in incidence across all ages, including infants who are not eligible for varicella vaccination, and adults, in whom vaccination levels are low, provide evidence of the benefit of high levels of immunity in the population.

Epidemiology of Breakthrough Varicella after the Implementation of a Universal Varicella Vaccination Program in Taiwan, 2004–2014

The study showed the incidence of varicella, BV andvaricella-related hospitalizations in Taiwan were kept low in post-vaccine era.

Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015

Varicella is associated with substantial clinical burden in Hungary, resulting in the utilization of a significant amount of healthcare resources, and these results support the need for routine vaccination of all healthy children to reduce the varicella-associated disease burden.

Determinants of varicella breakthrough

Logistic regression showed that breakthrough disease was associated with duration of time from vaccination, and time between vaccination and virus exposure was longer among cases.

Outbreak of varicella in a highly vaccinated preschool population.

The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia

Policymakers should consider implementing UVV to reduce the burden of varicella disease in Slovenia by implementing 2-dose UVV strategies compared with no vaccination.

Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model

The findings support adding a second varicella vaccine dose in Turkey, as doing so is highly cost-effective across a wide range of assumptions regarding the burden associated withvaricella and HZ disease.
...

References

SHOWING 1-10 OF 50 REFERENCES

Varicella vaccine effectiveness in the US vaccination program: a review.

Although 1 dose of varicella vaccine has provided excellent protection, a higher degree of effectiveness is needed in order to interrupt transmission and to prevent outbreaks in settings with high contact rates.

Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy.

The live attenuated varicella vaccine is highly effective in inducing persistent immunity and long-term protection against breakthroughvaricella infection.

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

Administration of either one or two injections of varicella vaccine to healthy children results in long term protection against mostvaricella disease.

Loss of vaccine-induced immunity to varicella over time.

A second dose of varicella vaccine, now recommended for all children, could improve protection from both primary vaccine failure and waning vaccine-induced immunity.

Postmarketing evaluation of the safety and effectiveness of varicella vaccine.

In this study population of 89753 children and adults, the varicella vaccine appeared to have a favorable safety profile, and rates ofvaricella-like rash and of breakthrough cases were both low and consistent with the rates observed in prelicensure studies.

Effectiveness of 2 doses of varicella vaccine in children.

The effectiveness of 2 doses of varicella vaccine in the first 2.5 years after recommendation of a routine second dose of the vaccine for children is excellent, and odds of developing varICElla were 95% lower for children who received 2 doses compared with 1 dose.

One Dose of Varicella Vaccine Does Not Prevent School Outbreaks: Is it Time for a Second Dose?

Although disease was mostly mild, the outbreak lasted for ∼2 months, suggesting that varicella in vaccinated persons was contagious and that 99%varicella vaccination coverage was not sufficient to prevent the outbreak, this investigation highlights several challenges related to the prevention and control of variceLLA outbreaks.

Varicella disease after introduction of varicella vaccine in the United States, 1995-2000.

Varicella disease has declined dramatically in surveillance areas with moderate vaccine coverage, with the greatest extent among children aged 1 to 4 years, but cases declined in all age groups, including infants and adults.

Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease

Varicella rates were similar in the 5- to 9- and 10- to 14-year age groups to rates from other published studies conducted in 1972 to 1978, 1980 to 1988 and 1990 to 1992; however, the rate in 15- to 19-year-olds was 2 to 4 times higher than published rates in the same age category.

Live attenuated varicella virus vaccine. Efficacy trial in healthy children.

The live attenuated Oka/Merck varicella vaccine produced few clinical reactions and was well tolerated, and there was no clinical evidence of viral spread from vaccinated children to sibling controls.